528 filings
10-K
2023 FY
FOLD
Amicus Therapeutics Inc
Annual report
28 Feb 24
4:08pm
8-K
FOLD
Amicus Therapeutics Inc
28 Feb 24
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
7:02am
8-K
FOLD
Amicus Therapeutics Inc
8 Jan 24
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
7:01am
8-K
FOLD
Amicus Therapeutics Inc
5 Dec 23
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
6:03am
S-3ASR
FOLD
Amicus Therapeutics Inc
8 Nov 23
Automatic shelf registration
5:25pm
8-K
w3gxzb
8 Nov 23
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
7:00am
D
csj123omyw90
16 Oct 23
$30.00 mm in equity, sold $30.00 mm, 2 investors
4:56pm
8-K
be1s0cszspt6wt1o
5 Oct 23
Termination of a Material Definitive Agreement
5:00pm
8-K
823qc0oa4wkls7r 1rg
2 Oct 23
Entry into a Material Definitive Agreement
8:48am
8-K
5or4e54 iqtfay
28 Sep 23
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
12:00pm
8-K
n6sl xgls
27 Sep 23
AT THE FOREFRONT OF THERAPIES FOR RARE DISEASES Corporate Overview September 2023
7:00am
8-K
cresfqkxec1tr4lv30
21 Aug 23
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
7:01am
8-K
fexn 6sj52q2h0e
15 Aug 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
7:00am
8-K
tsopfdbc qsz9od
8 Aug 23
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
7:00am
8-K
tqjo2ksxw4v41dlgvxw
13 Jul 23
Departure of Directors or Certain Officers
5:00pm
8-K
bkm m8k4b3hszzo
27 Jun 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
7:01am
S-8
xxc8shog 0x9
13 Jun 23
Registration of securities for employees
5:06pm
8-K
7m0dx
13 Jun 23
Amendments to Articles of Incorporation or Bylaws
4:30pm